Market Place
Sourcing Support
Spur Therapeutics to Join B. Riley Tissue Delivery Summit
07 Nov 2024 //
GLOBENEWSWIRE
Spur Therapeutics Publishes Preclinical Data for SBT101 in AMN
31 Oct 2024 //
GLOBENEWSWIRE
Spur Therapeutics Show Data From Gallileo-1 Trial Annual Congress
23 Oct 2024 //
GLOBENEWSWIRE
Spur To Present FLT201 Gaucher Data At ESGCT 31st Congress
03 Oct 2024 //
GLOBENEWSWIRE
Spur To Join Chardan Genetic Medicines Conference
23 Sep 2024 //
GLOBENEWSWIRE
Spur Therapeutics To Attend HC Wainwright Neuro Perspectives Conference
20 Jun 2024 //
GLOBENEWSWIRE
Spur Therapeutics Announces New Name And Brand
17 Jun 2024 //
GLOBENEWSWIRE
Freeline Therapeutics Rebrands to Spur Therapeutics
17 Jun 2024 //
CONTRACT PHARMA
Freeline Positive Gaucher Gene Therapy Data At ASGCT 2024
09 May 2024 //
GLOBENEWSWIRE
Freeline Presents Gaucher, Parkinson`s Data at ASGCT Annual Meeting
24 Apr 2024 //
GLOBENEWSWIRE
Acquisition of Freeline by Syncona Becomes Effective
20 Feb 2024 //
GLOBENEWSWIRE
Freeline Shareholders Approve Acquisition by Syncona
12 Feb 2024 //
GLOBENEWSWIRE
Syncona to Acquire Freeline Therapeutics
22 Nov 2023 //
GLOBENEWSWIRE
Syncona throws lifeline to Freeline by buying struggling biotech
22 Nov 2023 //
FIERCE BIOTECH
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201
25 Oct 2023 //
GLOBENEWSWIRE
Freeline, facing fading cash runway, mulls buyout by Syncona
19 Oct 2023 //
FIERCE BIOTECH
Syncona eyes buyout of gene therapy biotech Freeline
18 Oct 2023 //
ENDPTS
Freeline to Present New Data for FLT201 in Gaucher Disease in Presentation
16 Oct 2023 //
GLOBENEWSWIRE
Freeline Reports Positive Data from Phase 1/2 GALILEO-1 Trial of FLT201
04 Oct 2023 //
GLOBENEWSWIRE
Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
15 Aug 2023 //
GLOBENEWSWIRE
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
08 Aug 2023 //
GLOBENEWSWIRE
Freeline to Participate in Upcoming Investor Conferences
31 Jul 2023 //
GLOBENEWSWIRE
Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201
25 Jul 2023 //
GLOBENEWSWIRE
Freeline Announces First Patient Dosed with Gene Therapy Candidate for Gaucher Disease
26 Jun 2023 //
GLOBENEWSWIRE
Freeline to Present at 2023 Jefferies Healthcare Conference
02 Jun 2023 //
GLOBENEWSWIRE
Freeline Reports First Quarter 2023 Financial Results and Business Highlights
30 May 2023 //
GLOBENEWSWIRE
Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201
22 May 2023 //
GLOBENEWSWIRE
Freeline Completes ADS Ratio Change
12 May 2023 //
GLOBENEWSWIRE
Freeline Announces Proposed ADS Ratio Change
21 Apr 2023 //
GLOBENEWSWIRE
Freeline to Present at 22nd Annual Needham Virtual Healthcare Conference
12 Apr 2023 //
GLOBENEWSWIRE
Freeline cans another 30% of its staff months after last layoffs
05 Apr 2023 //
FIERCE BIOTECH
Viridian Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Apr 2023 //
GLOBENEWSWIRE
Forcefield signs exclusive patent and know-how license agreement with Freeline
04 Apr 2023 //
GLOBENEWSWIRE
Freeline Reports Full Year 2022 Financial Results and Provides Corporate Update
04 Apr 2023 //
GLOBENEWSWIRE
Freeline Therapeutics to Host Full Year 2022 Financial Results Call
28 Mar 2023 //
GLOBENEWSWIRE
Freeline Announces Closing of Sale of Its CMC-Focused German Subsidiary
10 Feb 2023 //
GLOBENEWSWIRE
Freeline Reports January Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Feb 2023 //
GLOBENEWSWIRE
Freeline Publishes Preclinical Proof-of-Concept Data for FLT190
19 Jan 2023 //
GLOBENEWSWIRE
Freeline Receives Approval to Transfer to Nasdaq Capital Market
29 Nov 2022 //
GLOBENEWSWIRE
Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing
05 Oct 2022 //
GLOBENEWSWIRE
Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190
04 Oct 2022 //
GLOBENEWSWIRE
Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing
06 Sep 2022 //
GLOBENEWSWIRE
Freeline Reports Second Quarter 2022 Financial Results and Business Highlights
09 Aug 2022 //
GLOBENEWSWIRE
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Aug 2022 //
GLOBENEWSWIRE
Freeline: June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Jul 2022 //
GLOBENEWSWIRE
Freeline to Present New Clinical Data for FLT180a in Hemophilia B
24 Jun 2022 //
GLOBENEWSWIRE
Freeline Initiates Dosing of Second Cohort in Dose Confirmation Trial of FLT180a
14 Jun 2022 //
GLOBENEWSWIRE
Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price
03 Jun 2022 //
GLOBENEWSWIRE
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Jun 2022 //
GLOBENEWSWIRE
Freeline Reports First Quarter 2022 Financial Results and Business Highlights
10 May 2022 //
GLOBENEWSWIRE
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 May 2022 //
GLOBENEWSWIRE
Freeline To Present at the 25th ASGCT
02 May 2022 //
GLOBENEWSWIRE
Freeline Appoints Paul Schneider as Chief Financial Officer
19 Apr 2022 //
GLOBENEWSWIRE
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Apr 2022 //
GLOBENEWSWIRE
Freeline Reports Full Year 2021 Financial Results and Business Highlights
31 Mar 2022 //
GLOBENEWSWIRE
Freeline Shows Updated Development Plan, Timelines for FLT190 in Fabry Disease
24 Mar 2022 //
GLOBENEWSWIRE
Freeline to Participate in Upcoming Investor Conferences
23 Mar 2022 //
GLOBENEWSWIRE
Talis Biomedical Reports Q4 and FY 2021 Financial Results
15 Mar 2022 //
GLOBENEWSWIRE
Freeline says $26.1 M Registered Direct Offering of American Depositary Shares
10 Mar 2022 //
GLOBENEWSWIRE
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Mar 2022 //
GLOBENEWSWIRE
